Discover how prime editing is redefining the future of medicine by offering highly precise, safe, and versatile DNA corrections, bringing hope for more effective treatments for genetic diseases while ...

Toward the goal of efficient editing of farm animals for genetic improvements, this study explores an upgraded form of nuclease PE (uPEn). Based on an initial demonstration of its success in editing ...

SAN FRANCISCO—Prime Medicine is on track to file the first IND/CTA application for human trials of a prime editing therapy to the FDA during the first half of this year, with the first clinical data ...

Despite the copious demands of his administrative positions as the White House chief science advisor (and until last year, the director of the NIH), Francis Collins, MD, PhD, has continued to run a ...

In a study published in Nature Biotechnology, GAO Caixia's group from the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences has developed a series of new prime editors ...

Prime editors delivered via a new type of particle have partially restored vision in blind mice. In a study published Jan. 8 in Nature Biotechnology, a research team from Harvard University and the ...

For babies born with alternative hemiplegia of childhood (AHC), an extremely rare and severe neurodevelopmental disorder, there may be no obvious symptoms for several months. Then the attacks begin: ...

Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...

Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive enzymes towards invading bacteriophages that express ...